Paper

Drug Safety in Crohn's Disease Therapy
Pascal Juillerat^a, Valérie Pittet^c, Christian Felley^a, Christian Mottet^a, Florian Froehlich^{a, b}, John-Paul Vader^c, Jean-Jacques Gonvers^a, Pierre Michetti<sup>a

a</sup>Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne,
^bGastrointestinal Department, University of Basle, Basle, and
^cHealthcare Evaluation Unit, Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland

Address of Corresponding Author

Digestion 2007;76:161-168 (DOI: 10.1159/000111031)

  Key Words

• Crohn's disease
• Inflammatory bowel disease
• Crohn's disease, treatment
• Drugs, safety
• Drug toxicity
• Immunosuppression

  Abstract

The management of Crohn's disease usually consists of a succession of short-term acute phase treatments followed by a long-term maintenance therapy. Above all the most frequent adverse events and the data on the long-term safety of the therapeutic arsenal available to the physician will be taken into consideration. The drugs described in this article include 5-ASA compounds, antibiotics (metronidazole, ciprofloxacin and rifaximin), corticosteroids (budesonide, prednisone and equivalents), thiopurines (azathioprine and 6-mercaptopurine), methotrexate, anti-tumor necrosis factor inhibitors (infliximab, adalimumab, certolizumab), natalizumab, anticalcineurin inhibitors (cyclosporine, tacrolimus) and mycophenolate mofetil.

Copyright © 2008 S. Karger AG, Basel

  Author Contacts

Pascal Juillerat, MD
Division of Gastroenterology and Hepatology
Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46
CH-1011 Lausanne (Switzerland)
Tel. +41 21 314 05 64, Fax +41 21 314 06 84, E-Mail pascal.juillerat@chuv.ch

  Article Information

Published online: February 7, 2008
Number of Print Pages : 8
Number of Figures : 0, Number of Tables : 0, Number of References : 85